Home » Stocks » Akorn

Akorn, Inc. (AKRX)

Jun 1, 2020 - AKRX was delisted due to bankruptcy and now trades as AKRXQ
Stock Price: $0.0900 USD 0.0000 (0.00%)
Updated May 29, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 11.98M
Revenue (ttm) 721.25M
Net Income (ttm) -401.32M
Shares Out 133.15M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 29, 2020
Last Price $0.0900
Previous Close $0.0900
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.1800
Day's Range 0.0900 - 0.1950
Day's Volume 36,138,501
52-Week Range 0.0900 - 5.4600

More Stats

Market Cap 11.98M
Enterprise Value 817.26M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 133.15M
Float 100.67M
EPS (basic) -3.16
EPS (diluted) -3.17
FCF / Share -0.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.92M
Short Ratio 0.49
Short % of Float 10.29%
Beta 1.14
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.02
PB Ratio 0.12
Revenue 721.25M
Operating Income -369.50M
Net Income -401.32M
Free Cash Flow -99.37M
Net Cash -805.27M
Net Cash / Share -6.05
Gross Margin 35.04%
Operating Margin -51.23%
Profit Margin -55.60%
FCF Margin -13.78%
ROA -0.94%
ROE -231.80%
ROIC -72.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 0
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$2.00*
(2,122% upside)
Low
2.00
Current: $0.0900
High
2.00
Target: 2.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue6826948411,11798555531825613786.41
Revenue Growth-1.67%-17.48%-24.69%13.38%77.48%74.7%24.03%87.09%58.46%-
Gross Profit25324643267459626117214979.6942.47
Operating Income-188-388-22.8832329560.8288.2068.7633.2711.27
Net Income-227-402-24.5518415113.8852.3635.3843.0121.82
Shares Outstanding12612512512311710396.1895.1994.5592.80
Earnings Per Share-1.80-3.21-0.201.471.220.130.460.320.410.22
EPS Growth---20.49%838.46%-71.74%43.75%-21.95%86.36%-
Operating Cash Flow-36.92-68.8924816729840.4457.3326.2419.6612.28
Capital Expenditures-30.40-69.13-90.56-68.97-25.4829.46-11.64-20.45-11.50-4.71
Free Cash Flow-67.32-13815797.7227269.9045.685.798.157.57
Cash & Equivalents14522536820235277.9534.1840.7883.9641.62
Total Debt8688208158101,0471,125109105101-
Net Cash / Debt-723-596-447-608-695-1,047-74.57-63.86-16.8541.62
Assets1,2891,4951,9101,9742,0431,894432370307111
Liabilities1,0541,0511,0781,1551,4211,53817216814924.36
Book Value23444483181962235626020115886.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akorn, Inc.
Country United States
Employees 2,227
CEO Douglas S. Boothe

Stock Information

Ticker Symbol AKRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AKRX

Description

Akorn, Inc., a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Further, the company sells its products to wholesale distributors. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. On May 20, 2020, Akorn, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.